Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.82%||165.21||0.7%||$968.47m|
|MRK||Merck & Co., Inc.||-0.69%||80.73||0.7%||$855.87m|
|BMY||Bristol-Myers Squibb Co.||-0.17%||64.61||1.0%||$688.01m|
|LLY||Eli Lilly & Co.||-0.76%||243.20||1.1%||$618.76m|
|NVO||Novo Nordisk A/S||-1.86%||95.48||0.1%||$152.14m|
|IMMX||Immix Biopharma, Inc.||-4.24%||5.42||0.0%||$85.02m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.87%||116.04||0.0%||$72.25m|
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism; as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Boston, MA.